Ethereum is the second largest cryptocurrency by market cap, behind Bitcoin. Ethereum is a decentralized opensource blockchain and the center of the world of decentralized finance (Defi).

Many people are excited about the upcoming upgrade to the Ethereum Network. This upgrade is called Ethereum 2.0 Serenity. This upgrade is designed to provide users with increased security, performance, and scalability. The purpose of this article is to highlight some of the key reasons that several individuals and organizations are excited about Ethereum 2.0.

Ethereum 2.0 allows users to take advantage of features such as Proof of Stake. Proof of stake is…


Have you thought about starting a consulting business? It seems almost everyone is a consultant these days. Technology, management, social media, financial, operations, and more. Everyone is a consultant and there are many reasons why you should. But, how do you go about it? How do you separate yourself from the growing pack of consultants?

In most of these fields, the client already has a good understanding of what he or she wants done; however, the client just need a little guidance on how to carry out that plan. This is where you come into play. If you have knowledge…


Article Forge has become one of the most popular automated writing services, and it is easy to see why. With a high number of articles submitted each day, it has the potential to make you a very profitable writer! Artificial intelligence (AI) written articles in less than one minute, incredible. With Article Forge, the days of staring at blank text are OVER! What a time to be alive!

How does it work? Article Forge uses artificial intelligence software to write unique articles with virtually the same content as a regular human for far less money and time. The main idea…


So often, you may find yourself in front of the computer staring at the blinking cursor feeling like it’s judging you because you can’t think of anything to say. Welcome to blogging. The cursor doesn’t think anything, by the way, but when it comes to composing blogs for the means of brand marketing, we can be quite hard on ourselves.

It can be challenging, especially when we’re first starting out on this journey that is personal branding. …


A social media startup that actually shares revenue with users… What a concept in this day and age of influencers and instantaneous connection through social media, isn’t it? No doubt you’re using one of the major apps every day in some way, shape, or form. Whether it be Facebook, Instagram, TikTok, you’re using it to keep in touch or connect in one way or another.

How can you not in the world we live in today? Being connected is everything, at all times. So many people have made a living influencing the lives of others. Built business around social networking…


*EDIT* When I wrote this in July there have been a few changes, these changes were for the price of Tesla (TSLA) and the NASDAQ ETF (QQQ). However, the underlying message of speculation remains.

The irrational speculation of US equities is baffling. NASDAQ is the new Bitcoin and the tech bubble 2.0 is coming. Many speculate that NASDAQ will be at 15,000 by the end of the year. Tesla has soared over 200% this year alone and just passed $1,500 a share. The bubble that is brewing will exceed the NASDAQ bubble that wiped out internet startups in a party…


The International Monetary Fund (IMF) projects that over 170 countries will experience negative per capita income growth in 2020. It is also predicted that the economic crisis that would result as a consequence of the global mobility restrictions would disproportionately affect lower-income workers. Bankruptcies are rising with the unemployment rate near record highs as countries like the United States continues to see positive tests for Covid-19. There is a fear of the new wave of the Covid-19 virus if economic activities kick start too quickly. …


Pipeline of gene therapy and retinal diseases drug candidates.

Stock is trading near all-time lows as of 7/6/2020.

Expansive gene therapy pipeline with FDA orphan designation of OCU400.

Insider purchases in recent months and no reported sales.

Discontinued phase trial of drug candidate OCU300.

On June 1, the company discontinued their Phase 3 trial of “OCU300” for ocular Graft vs. Host Disease (oGVHD).” This follows the results of a pre-planned interim sample size, which indicated that the trial is unlikely to meet co-primary endpoints upon completion.” Despite this, Ocugen’s stock closed up 11% on June 5, indicating the firm’s soaring optimism and anticipated recovery.

A Brief Background on Ocugen

Joseph Lizyness

US Army veteran | MBA | Entrepreneur | Investor in tech startups | Looking to join a venture capital (VC) firm. | Let’s change the world | Consultant

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store